1. Home
  2. KD vs RYTM Comparison

KD vs RYTM Comparison

Compare KD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

N/A

Current Price

$12.75

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$90.08

Market Cap

6.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KD
RYTM
Founded
2020
2008
Country
United States
United States
Employees
80000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
6.4B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
KD
RYTM
Price
$12.75
$90.08
Analyst Decision
Buy
Strong Buy
Analyst Count
5
14
Target Price
$35.25
$129.43
AVG Volume (30 Days)
5.2M
722.9K
Earning Date
05-11-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
170.95
28.34
EPS
0.77
N/A
Revenue
$15,057,000,000.00
N/A
Revenue This Year
$3.96
$57.46
Revenue Next Year
$0.41
$85.60
P/E Ratio
$16.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.10
$45.91
52 Week High
$43.74
$122.20

Technical Indicators

Market Signals
Indicator
KD
RYTM
Relative Strength Index (RSI) 36.01 39.84
Support Level $11.34 $85.59
Resistance Level $13.93 $96.92
Average True Range (ATR) 0.53 4.86
MACD 0.52 -0.29
Stochastic Oscillator 60.64 22.30

Price Performance

Historical Comparison
KD
RYTM

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Share on Social Networks: